TP53 Point Mutation, from molecular mechanisms to therapeutic strategies

Molecular Mechanisms and Biological Impact of TP53 Mutations: From TP53 Gene Dysfunction to Tumorigenesis and Therapeutic Strategies

The TP53 gene, also known as the p53 gene, is one of the most critical tumor suppressor genes in the human genome. Discovered in 1979 and recognized for its tumor-suppressive function in 1989, TP53 has since been regarded as the “guardian of the genome” and remains a central focus of cancer research.

Under normal physiological conditions, the TP53 gene functions as a tightly regulated stress-response hub . The p53 protein encoded by the TP53 gene is constantly produced but also rapidly degraded. Upon DNA damage, replication stress, or metabolic imbalance, p53 becomes stabilized and activated, allowing it to orchestrate cell fate decisions.

Rather than simply inducing apoptosis, p53 exerts a context-dependent regulatory role:

l In response to mild damage, p53 induces cell cycle arrest through transcriptional activation of targets such as p21, allowing time for DNA repair.

l Under moderate stress, p53 promotes DNA repair pathways and antioxidant responses.

l When damage is irreversible, p53 triggers apoptosis or cellular senescence to eliminate potentially malignant cells.

This context-dependent regulatory capacity makes the TP53 gene a central guardian of genomic stability.

In experimental studies, TP53 antibodies are widely used to assess p53 protein expression, conformational changes, and mutation-associated alterations, serving as essential tools for dissecting TP53 signaling activity and the functional consequences of TP53 mutations.

TP53 Point Mutations and Biological Consequences

When TP53 gene mutations occur, this finely tuned regulatory system collapses. In human cancers, TP53 mutations are predominantly point mutations, particularly missense mutations. These alterations can arise as:
l Somatic TP53 mutations, acquired during tumor development;
l Germline TP53 gene mutations, which are inherited and associated with Li-Fraumeni syndrome.

Fig. 1. General characteristics of mutp53. ^[1]

Most TP53 point mutations occur within the DNA-binding domain, leading to conformational changes in the p53 protein. As a result, mutant p53 may exhibit loss-of-function (LOF) or gain-of-function (GOF) properties, actively promoting tumorigenesis.The biological consequences of TP53 point mutations include:
l Increased cancer susceptibility, with germline TP53 mutation carriers showing a lifetime cancer risk exceeding 90%;
l Poor prognosis and therapy resistance, as mutant p53 tumors often display aggressive behavior and reduced sensitivity to radiotherapy and chemotherapy;
l System-level effects, where mutant p53 reshapes the tumor microenvironment, enhances angiogenesis, and facilitates immune evasion.

Therapeutic Strategies Targeting TP53 Mutations

Unlike kinase-driven oncogenic mutations, targeting TP53 mutations remains challenging due to the complexity of the p53 signaling network and the heterogeneity of TP53 gene mutations. Current research directions include:

1. Reactivation of mutant p53
Small molecules, metal ion coordination, and structural stabilizers are being developed to restore wild-type–like conformation and activity in specific TP53 mutations.

2. Synthetic lethality approaches
TP53-deficient tumors rely on alternative DNA repair pathways. By targeting these compensatory mechanisms, synthetic lethality strategies selectively eliminate cancer cells.

In addition, tumors harboring TP53 mutations often exhibit a high mutational burden, making them more responsive to immunotherapies such as immune checkpoint inhibitors.

EDITGENE has established a comprehensive portfolio of TP53 gene-edited cell lines, including TP53 point mutation and TP53 knockout models. These standardized and functionally validated cell models support mechanistic studies, drug discovery, and translational cancer research.

Point Mutation Cell Line

Catalog	Cell Name	Gene	PM Site/Locus	Functional Domain	Order Now

EDC03134	HCT116	TP53	p.V157F	DNA-binding domain (DBD)	Order
EDC03127	HCT116	TP53	p.V157G	DNA-binding domain (DBD)	Order
EDC03143	HCT116	TP53	p.R158G	DNA-binding domain (DBD)	Order
EDC03089	HCT116	TP53	p.R158C	DNA-binding domain (DBD)	Order
EDC03088	HCT116	TP53	p.R158H	DNA-binding domain (DBD)	Order
EDC03092	HCT116	TP53	p.R158L	DNA-binding domain (DBD)	Order
EDC03063	HCT116	TP53	p.H179R	DNA-binding domain (DBD)	Order
EDC03133	HCT116	TP53	p.C242Y	DNA-binding domain (DBD)	Order
EDC03093	HCT116	TP53	p.G245S	DNA-binding domain (DBD)	Order
EDC03099	HCT116	TP53	p.G245C	DNA-binding domain (DBD)	Order
EDC03095	HCT116	TP53	p.G245D	DNA-binding domain (DBD)	Order
EDC03132	HCT116	TP53	p.G245V	DNA-binding domain (DBD)	Order
EDC03094	HCT116	TP53	p.R248W	DNA-binding domain (DBD)	Order
EDC03171	HCT116	TP53	p.R248L	DNA-binding domain (DBD)	Order
EDC03087	HCT116	TP53	p.R249G	DNA-binding domain (DBD)	Order
EDC03086	HCT116	TP53	p.R249W	DNA-binding domain (DBD)	Order
EDC03118	HCT116	TP53	p.R249M	DNA-binding domain (DBD)	Order
EDC03117	HCT116	TP53	p.R249S	DNA-binding domain (DBD)	Order
EDC03109	HCT116	TP53	p.R273C	DNA-binding domain (DBD)	Order
EDC03170	HCT116	TP53	p.R273H	DNA-binding domain (DBD)	Order
EDC03110	HCT116	TP53	p.D281G	DNA-binding domain (DBD)	Order
EDC03100	HCT116	TP53	p.R282G	DNA-binding domain (DBD)	Order
EDC03621	HAP1	TP53	p.P72R	Proline-rich domain (PRD)	Order
EDC03619	HAP1	TP53	c.673-36G>C	/	Order
EDC03620	HAP1	TP53	c.376-91G>A	/	Order

KO Cell Line

Catalog	Cell Name	Gene	Order Now

EDC07854	HCT116	TP53	Order
EDJ-KQ17910	HEK293	TP53	Order
EDJ-KQ18086	HeLa	TP53	Order
EDJ-KQ18198	A549	TP53	Order

Leveraging the newly developed Bingo™ Platform , EDITGENE applies an optimized Prime Editing (PE7 system) to introduce precise point mutations with editing efficiencies exceeding 90% at the target locus.

This advanced gene-editing strategy enables the generation of high-efficiency, genetically stable point mutation cell lines, all of which are molecularly validated and suitable for basic research and drug discovery applications.

Catalog	Cell Name	Gene	Gene ID	PM Site/Locus	Order Now

EDC03196	HCT116	KRAS	3845	p.G13C	Order
EDC03199	HCT116	KRAS	3845	p.Q61H	Order
EDC03203	HCT116	KRAS	3845	p.G12S	Order
EDC03206	HCT116	KRAS	3845	p.G12R	Order
EDC03208	HCT116	KRAS	3845	p.G12C	Order
EDC03038	HCT116	KRAS	3845	p.G12V	Order
EDC03030	HCT116	KRAS	3845	p.G13S	Order
EDC03035	HCT116	KRAS	3845	p.G13R	Order
EDC03211	HCT116	EGFR	1956	p.Q787R	Order
EDC03053	HCT116	GJB2	2706	p.V13fs	Order
EDC03057	HCT116	GJB2	2706	p.V37I	Order
EDC03054	HCT116	GJB3	2707	p.C165T	Order
EDC03102	HCT116	SLC26A4	5172	p.L676Q	Order
EDC03125	HCT116	SLC26A4	5172	p.G197R	Order
EDC03106	HCT116	SLC26A4	5172	p.T410M	Order
EDC03107	HCT116	SLC26A4	5172	p.H723R	Order
EDC03080	HCT116	G6PD	2539	p.G131V	Order
EDC03076	HCT116	G6PD	2539	p.V291M	Order
EDC03181	K562	G6PD	2539	p.H32R	Order
EDC03077	HCT116	G6PD	2539	p.H32R	Order
EDC03108	HCT116	G6PD	2539	p.L342F	Order
EDC03152	K562	G6PD	2539	p.L342F	Order
EDC03168	K562	G6PD	2539	p.R459L	Order
EDC03134	HCT116	TP53	7157	p.V157F	Order
EDC03127	HCT116	TP53	7157	p.V157G	Order
EDC03143	HCT116	TP53	7157	p.R158G	Order
EDC03092	HCT116	TP53	7157	p.R158L	Order
EDC03063	HCT116	TP53	7157	p.H179R	Order
EDC03133	HCT116	TP53	7157	p.C242Y	Order
EDC03093	HCT116	TP53	7157	p.G245S	Order
EDC03095	HCT116	TP53	7157	p.G245D	Order
EDC03132	HCT116	TP53	7157	p.G245V	Order
EDC03171	HCT116	TP53	7157	p.R248L	Order
EDC03118	HCT116	TP53	7157	p.R249M	Order
EDC03117	HCT116	TP53	7157	p.R249S	Order
EDC03109	HCT116	TP53	7157	p.R273C	Order
EDC03170	HCT116	TP53	7157	p.R273H	Order
EDC03110	HCT116	TP53	7157	p.D281G	Order
EDC03100	HCT116	TP53	7157	p.R282G	Order
EDC03101	HCT116	AKT1	201	p.E17K	Order
EDC03055	HCT116	ESR1	2099	p.Y537N	Order
EDC03214	HCT116	ESR1	2099	p.Y537S	Order
EDC03075	HCT116	FGFR3	2261	p.R248C	Order
EDC03175	HCT116	FGFR3	2261	p.Y373C	Order
EDC03105	HCT116	HRAS	3265	p.Q61K	Order
EDC03111	HCT116	HRAS	3265	p.G13R	Order
EDC03081	HCT116	HRAS	3265	p.Q61R	Order
EDC03112	HCT116	HRAS	3265	p.G12D	Order
EDC03179	HCT116	IDH1	3417	p.R132H	Order
EDC03184	HCT116	IDH2	3418	p.R172M	Order
EDC03176	HCT116	KIT	3815	p.V559A	Order
EDC03120	HCT116	KIT	3815	p.V560D	Order
EDC03119	HCT116	MAP2K1	5604	p.P124S	Order
EDC03121	HCT116	MAP2K1	5604	p.E203K	Order
EDC03177	HCT116	NRAS	4893	p.Q61R	Order
EDC03123	HCT116	NRAS	4893	p.G12S	Order
EDC03074	HCT116	NRAS	4893	p.G12C	Order
EDC03122	HCT116	NRAS	4893	p.G13R	Order
EDC03072	HCT116	NRAS	4893	p.G13D	Order
EDC03079	HCT116	PTEN	5728	p.R130G	Order
EDC03115	HCT116	PTEN	5728	p.R233*	Order
EDC03126	HCT116	PTEN	5728	p.R130L	Order
EDC03129	HCT116	PTEN	5728	p.R173H	Order
EDC03114	HCT116	RB1	5925	p.R579*	Order
EDC03116	HCT116	RB1	5925	p.R251*	Order
EDC03033	HCT116	EGFR	1956	p.S768I	Order
EDC07731	A549	G3BP1	10146	p.S373G	Order
EDC03185	A549	USP24	23358	NC_000001.11:g.55132659 T>C & 55132661 T>C	Order
EDC03187	A549	PDZD7	79955	p.K790E	Order
EDC03189	AC16	GLA	2717	p.D155E	Order
EDC03141	HEPG2	SLC37A4	2542	NC_000011.10:g.119025190C>A	Order
EDC03192	HCT116	TOPBP1	11073	p.T1105A	Order

References

1. Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X, Lei H, Wang J, Xie X, Cheng B, Li Q, Zhang H, Di C. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2022 Nov 18;13(11):974.